discgenics - search results

If you're not happy with the results, please do another search
idct

DiscGenics receives FDA fast track designation for disc degeneration cell therapy

DiscGenics has announced that the US Food and Drug Administration (FDA) has granted fast track designation for its investigational cell therapy, IDCT, currently being...
DiscGenics logo

DiscGenics’ IDCT Investigational New Drug application accepted by US FDA

DiscGenics has been notified by the US Food and Drug Administration (FDA) that an Investigational New Drug (IND) application for a clinical study of...

DiscGenics granted 9 new patents for DiscoGenic Cell technology

DiscGenics has been granted 9 new patents, expanding its intellectual property portfolio within both the US and globally to 24 issued patents. The new...

IDCT clinical study passes final safety review

DiscGenics has announced that it has received the go-ahead from an independent data safety monitoring committee (DSMC) to enrol the final 24 patients in...
IDCT

First patients treated in Japanese clinical trial of cell therapy for DDD

DiscGenics today announced the first patients have been treated in its Japanese safety study, a clinical trial of IDCT for mild to moderate degenerative...
IDCT

Cell therapy IDCT passes initial safety review of first-in-human clinical trial for DDD

It has been announced that IDCT (DiscGenics) has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc...
IDCT

Clinical evaluation of non-surgical degenerative disc disease treatment to begin in Japan

The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved a Clinical Trial Notification (CTN) application for IDCT (DiscGenics), an allogenic injectable disc cell...
IDCT

First patient treated in US clinical trial of IDCT for degenerative disc disease

DiscGenics, a clinical stage regenerative medicine company, has announced the first patient has been treated in its phase I/II US clinical trial of IDCT...
IDCT

Preclinical studies of a non-invasive cell therapy for DDD highlight its safety and efficacy

Two preclinical studies of IDCT, an allogenic (donor-derived), non-invasive cell therapy for the treatment of degenerative disc disease (DDD), demonstrate that proprietary discogenic cells,...

Tim Pigott

Ronald Bartels

Matthew Scott-Young